Recdect/PTO 21 DEC 2005

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no pe	rsons are required to respond to a col	atent and Trademar lection of information	k Office; t unless it	J.S. DEPARTMENT OF COMMERCE displays a valid OMB control number.	
	Application Number	10k/517,214			
TRANSMITTAL	Filing Date	11/23/2004			
FORM	First Named Inventor	T. MAEKAWA			
	Art Unit	tba			
(to be used for all correspondence after initial filing)	Examiner Name	tba			
Total Number of Pages in This Submission 16	Attorney Docket Number	Attorney Docket Number 3065 US0P			
ENCLOSURES (Check all that apply) After Allowance Communication to TC					
Fee Transmittal Form	Drawing(s)		Appea	Il Communication to Board	
Fee Attached	Licensing-related Papers			eals and Interferences	
Document(s) The	Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Emarks Commissioner is hereby authorized the control of the contr	Retu Cert Sub IBM Cop	Propri Status Other below um Poste ificate or mission PC/AT if	card; i Express Mailing; of Written Sequence Listing; format disk; fication to Comply	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name					
Signature					
Printed name Mark Chao, Ph.D., JD					
Date 12/11/05	F	Reg. No. 37,29	3	<u>,</u>	
1 12 H 100					
CERTIFICATE OF TRANSMISSION/MAILING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:					
Signature Sail L. Winoku					
Typed or printed name Gail L. Winokur			Date	12/21/2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Expres Mail 70. EV 684083839 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/517,214

11/23/2004

1st Inventor:

T. MAEKAWA

For:

Filed:

1,2-Azole Derivatives with Hypoglycemic and

Hypolipedemic Activity

Atty. Dkt. No.

3065 US0P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

Paper No.

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 684083839 US

DATE IN:

December 21, 2005

Itemized Papers/Items:

- 1. This Certificate of Express Mailing and Return Postcard (2 pages)
- 2. Transmittal Form (1 page X 2)
- 3. Response to Notice to Comply with Sequence Listing Requirements (1 page), Submission of Written Sequence Listing (3 pages), IBM PC/AT format disk containing the CRF of the Sequence Listing,
- 4. Copy of Notification to Comply (8 pages).

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP SEQUENCE Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

on this date, December 21, 2005

Dated: 12/21/05

Gail L. Winokur

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA

PRIORITY DATE

05/24/2002



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

ATTY. DOCKET NO. FIRST NAMED APPLICANT U.S. APPLICATION NUMBER NO. 3065 US0P Tsuyoshi Maekawa 10/517.214

INTERNATIONAL APPLICATION NO.

PCT/JP03/06389

23115 I.A. FILING DATE TAKEDA PHARMACEUTICALS NORTH AMERICA, INC INTELLECTUAL PROPERTY DEPARTMENT 05/22/2003

DEC

475 HALF DAY ROAD SUITE 500

LINCOLNSHIRE, IL 60069

CONFIRMATION NO. 7396

371 FORMALITIES LETTER

OC000000017640406

Date Mailed: 12/13/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

P. DEPT

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

16

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.


KAREN M WILLIAMS


Telephone: (703) 308-9140 EXT 213

PART 1 - ATTORNEY/APPLICANT COPY

		ATTIV DOCKET NO
U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/517,214	PCT/JP03/06389	3065 US0P

FORM PCT/DO/EO/922 (371 Formalities Notice)





The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

Source

Date Processed by STIC:

10/5/7/214

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm , EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
 U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04



PCT

RAW SEQUENCE LISTING

DATE: 12/22/2004

PATENT APPLICATION: US/10/517,214

TIME: 09:16:36

Input Set : A:\3065 USOP seg.txt

Output Set: N:\CRF4\12222004\J517214.raw

```
2 <110> APPLICANT: MAEKAWA, Tsuyoshi
              HARA, Ryoma
              ODAKA, Hiroyuki
              MIZUFUNE, Hideya
              FUKATSU, Kohji
      8 <120> TITLE OF INVENTION: 1,2-Azole Derivatives with Hypoglycemic and Hypolipidemic
Activity
     10 <130> FILE REFERENCE: 3065 USOP
C--> 12 <140> CURRENT APPLICATION NUMBER: US/10/517,214
C--> 12 <141> CURRENT FILING DATE: 2004-11-23
     12 <150> PRIOR APPLICATION NUMBER: PCT/JP03/06389
     13 <151> PRIOR FILING DATE: 2003-05-22
     15 <150> PRIOR APPLICATION NUMBER: JP 2002-151405
     16 <151> PRIOR FILING DATE: 2002-05-24
     18 <150> PRIOR APPLICATION NUMBER: JP 2002-287161
     19 <151> PRIOR FILING DATE: 2002-09-30
     21 <150> PRIOR APPLICATION NUMBER: JP 2003-016748
     22 <151> PRIOR FILING DATE: 2003-01-24
     24 <160> NUMBER OF SEQ ID NOS: 12
     26 <210> SEO ID NO: 1
     27 <211> LENGTH: 34
     28 <212> TYPE: DNA
     29 <213> ORGANISM: Artificial Sequence
W--> 30 <220> FEATURE:
     31 <223> OTHER INFORMATION: Primer/probe
     33 <400> SEQUENCE: 1
     34 aacggtacct cagccatgga gcagcctcag gagg
     36 <210> SEQ ID NO: 2
     37 <211> LENGTH: 34
     38 <212> TYPE: DNA
     39 <213> ORGANISM: Artificial Sequence
W--> 40 <220> FEATURE:
     41 <223> OTHER INFORMATION: Primer/probe
     43 <400> SEQUENCE: 2
     44 taagtcgacc cgttagtaca tgtccttgta gatc
     46 <210> SEQ ID NO: 3
     47 <211> LENGTH: 33
     48 <212> TYPE: DNA
     49 <213> ORGANISM: Artificial Sequence
W--> 50 <220> FEATURE:
     51 <223> OTHER INFORMATION: Primer/probe
     53 <400> SEQUENCE: 3
```

Contested Cishelfo Age to

56 <210> SEQ ID NO: 4

54 ttagaattcg acatggacac caaacatttc ctg

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/517,214

DATE: 12/22/2004 TIME: 09:16:36

Input Set : A:\3065 USOP seq.txt

Output Set: N:\CRF4\12222004\J517214.raw

57 <211> LENGTH: 33

58 <212> TYPE: DNA

59 <213> ORGANISM: Artificial Sequence

W--> 60 <220> FEATURE:

61 <223> OTHER INFORMATION: Primer/probe

63 <400> SEQUENCE: 4

64 cccctcgagc taagtcattt ggtgcggcgc ctc

66 <210> SEQ ID NO: 5

67 <211> LENGTH: 36

68 <212> TYPE: DNA

69 <213> ORGANISM: Artificial Sequence

W--> 70 <220> FEATURE:

71 <223> OTHER INFORMATION: Primer/probe

73 <400> SEQUENCE: 5

74 tcgacagggg accaggacaa aggtcacgtt cgggag 36

78 <212> TYPE: DNA
79 <213> OBGANISM: Artificial Sequence
PLS PLAIN SOUTCE
81 (220> FEATURE:
82 <223> OTHER INFORMATION:) PLS INSERT
84 <400> 6
85 tcgactcccg aacgtgacct ttgtcctggt cccctg
86 <210> SEQ ID NO: 7
88 <211> LENGTH: 28
89 <212> TYPE: DNA
90 <213> ORGANISM: Artificial Sequence
91 <220> FEATURE:
92 <223> OTHER INFORMATION: Primer/probe
94 <400> SEQUENCE: 7
95 cccagatoto 3-1

W--> 91 <220> FEATURE:

95 cccagatctc cccagcgtct tgtcattg

97 <210> SEQ ID NO: 8

98 <211> LENGTH: 28

99 <212> TYPE: DNA

100 <213> ORGANISM: Artificial Sequence

W--> 101 <220> FEATURE:

102 <223> OTHER INFORMATION: Primer/probe

104 <400> SEQUENCE: 8

105 tcaccatggt caagctttta agcgggtc

107 <210> SEQ ID NO: 9

108 <211> LENGTH: 33

109 <212> TYPE: DNA

110 <213> ORGANISM: Artificial Sequence

W--> 111 <220> FEATURE:

112 <223> OTHER INFORMATION: Primer/probe

114 <400> SEQUENCE: 9

115 gtgggtaccg aaatgaccat ggttgacaca gag

117 <210> SEQ ID NO: 10

118 <211> LENGTH: 33

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/517,214

DATE: 12/22/2004 TIME: 09:16:36

Input Set : A:\3065 USOP seq.txt

Output Set: N:\CRF4\12222004\J517214.raw

- 119 <212> TYPE: DNA
- 120 <213> ORGANISM: Artificial Sequence
- W--> 121 <220> FEATURE:
 - 122 <223> OTHER INFORMATION: Primer/probe
 - 124 <400> SEQUENCE: 10
 - 125 ggggtcgacc aggactctct gctagtacaa gtc 33
 - 127 <210> SEQ ID NO: 11
 - 128 <211> LENGTH: 33
 - 129 <212> TYPE: DNA
 - 130 <213> ORGANISM: Artificial Sequence
- W--> 131 <220> FEATURE:
 - 132 <223> OTHER INFORMATION: Primer/probe
 - 134 <400> SEQUENCE: 11
 - 135 cgtcgacccg gcggccccat ggacctgccc ccg 33
 - 137 <210> SEQ ID NO: 12
 - 138 <211> LENGTH: 33
 - 139 <212> TYPE: DNA
 - 140 <213> ORGANISM: Artificial Sequence
- W--> 141 <220> FEATURE:
 - 142 <223> OTHER INFORMATION: Primer/probe
 - 144 <400> SEQUENCE: 12
 - 145 patcgattag cagtggcgtt acttctggga ctt 33
- W--> 146/9?
- W--> 148 ??
- W--> 150 ??
- W--> 152 ??

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/517,214

DATE: 12/22/2004 TIME: 09:16:37

Input Set : A:\3065 USOP seq.txt

Output Set: N:\CRF4\12222004\J517214.raw

L:12 M:270 C: Current Application Number differs, Replaced Current Application No L:12 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:30 M:283 W: Missing Blank Line separator, <220> field identifier L:40 M:283 W: Missing Blank Line separator, <220> field identifier L:50 M:283 W: Missing Blank Line separator, <220> field identifier L:60 M:283 W: Missing Blank Line separator, <220> field identifier L:70 M:283 W: Missing Blank Line separator, <220> field identifier L:84 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:6,Line#:82 L:91 M:283 W: Missing Blank Line separator, <220> field identifier L:101 M:283 W: Missing Blank Line separator, <220> field identifier L:111 M:283 W: Missing Blank Line separator, <220> field identifier L:121 M:283 W: Missing Blank Line separator, <220> field identifier L:131 M:283 W: Missing Blank Line separator, <220> field identifier L:141 M:283 W: Missing Blank Line separator, <220> field identifier L:146 M:334 W: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:1 L:148 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:12 L:148 M:334 W: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:1 L:150 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:12 L:150 M:334 W: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:1 L:152 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:12 L:152 M:334 W: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:1

STATISTICS SUMMARY

PATENT APPLICATION: US/10/517,214

DATE: 12/22/2004 TIME: 09:16:37

Input Set : A:\3065 USOP seq.txt

Output Set: N:\CRF4\12222004\J517214.raw

Application Serial Number: US/10/517,214

Alpha or Numeric or Xml: Numeric

Application Class:

Application File Date: 11-23-2004

Art Unit: PCT

Software Application:

Total Number of Sequences: 12

Total Nucleotides: 394
Total Amino Acids: 0
Number of Errors: 0
Number of Warnings: 19
Number of Corrections: 2

MESSAGE SUMMARY

258 W: 1 (Mandatory Feature missing)

270 C: 1 (Current Application Number differs)

271 C: 1 (Current Filing Date differs)

283 W: 11 (Missing Blank Line separator)

334 W: 4 ((2) Invalid Amino Acid in Coding Region)

336 W: 3 (Invalid Amino Acid Number in Coding Region)